Evidence map›Paper›PMID 33528827›Full record

ArticleJournal of neurovirology2021

Prevalence and correlates of chronic fatigue syndrome and post-traumatic stress disorder after the outbreak of the COVID-19.

Leila Simani, Mahtab Ramezani, Ilad Alavi Darazam, Mastooreh Sagharichi, Mohammad Amin Aalipour, Fatemeh Ghorbani, Hossein Pakdaman

2 registry-linked trialsOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neurovirology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 86 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed, 12 pooled it
23.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05323318 unknown statusnot on this mapstarted 2022, after this paper: background citation

Neuropsychological Sequelae as a Risk Factor for Long COVID-19 Fatigue

TypeobservationalSponsorCentro Hospitalar Universitario do AlgarveRan2022 to 2023Enrolled200ConditionsAnxiety Depression, Post Traumatic Stress Disorder, Mental Fatigue, COVID-19ArmsNeuropsychological Sequelae
NCT05630339 nacompletednot on this mapstarted 2022, after this paper: background citation

Efficacy and Security of the Magnesium and Vitamin D Combination as Adjuvant Treatment of Post-COVID Syndrome. A Randomised Double-blind Clinical Trial

TypeinterventionalSponsorCoordinación de Investigación en Salud, MexicoRan2022 to 2023Enrolled150ConditionsPost-COVID-19 Syndrome, Long COVID, Vitamin D Deficiency, Magnesium DeficiencyArmsMagnesium chloride, Vitamin D, Inert placebo
3 · Its place in the literature

Who cites it

86 citing papers in PubMed, 12 syntheses or guidelines pooled it, 164 citations in OpenAlex.

  1. Global prevalence of post-COVID-19 condition: a systematic review and meta-analysis of prospective evidence.Health promotion and chronic disease prevention in Canada : research, policy and practice · 2025
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. ESCMID rapid guidelines for assessment and management of long COVID.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2022
    Guideline
  6. Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: a systematic review and meta-analysis.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2022
    Pooled it
  7. Clinical patterns of somatic symptoms in patients suffering from post-acute long COVID: a systematic review.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2022
    Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Incidence and risk factors for persistent symptoms in adults previously hospitalized for COVID-19.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2021
    Trial
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review

26 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Leila SimaniSkull Base Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mahtab RamezaniSkull Base Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. drramezani23@gmail.com.ORCID http://orcid.org/0000-0002-1148-3998
Ilad Alavi DarazamDepartment of Infectious Diseases and Tropical Medicine, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mastooreh SagharichiSkull Base Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mohammad Amin AalipourSkull Base Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Fatemeh GhorbaniSkull Base Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Hossein PakdamanBrain Mapping Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Shahid Beheshti University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As the SARS-COV-2 becomes a global pandemic, many researchers have a concern about the long COVID-19 complications. Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is a persistent, debilitating, and unexplained fatigue disorder. We investigated psychological morbidities such as CFS and post-traumatic stress disorder (PTSD) among survivors of COVID-19 over 6 months. All COVID-19 survivors from the university-affiliated hospital of Tehran, Iran, were assessed 6 months after infection onset by a previously validated questionnaire based on the Fukuda guidelines for CFS/EM and DSM-5 Checklist for PTSD (The Post-traumatic Stress Disorder Checklist for DSM-5 or PCL-5) to determine the presence of stress disorder and chronic fatigue problems. A total of 120 patients were enrolled. The prevalence rate of fatigue symptoms was 17.5%. Twelve (10%) screened positive for chronic idiopathic fatigue (CIF), 6 (5%) for CFS-like with insufficient fatigue syndrome (CFSWIFS), and 3 (2.5%) for CFS. The mean total scores in PCL-5 were 9.27 ± 10.76 (range:0-44), and the prevalence rate of PTSD was 5.8%. There was no significant association after adjusting between CFS and PTSD, gender, comorbidities, and chloroquine phosphate administration. The obtained data revealed the prevalence of CFS among patients with COVID-19, which is almost similar to CFS prevalence in the general population. Moreover, PTSD in patients with COVID-19 is not associated with the increased risk of CFS. Our study suggested that medical institutions should pay attention to the psychological consequences of the COVID-19 outbreak.

Indexed as

AdultAgedAntiviral AgentsCoughCOVID-19COVID-19 Drug TreatmentDementiaDrug CombinationsDyspneaFatigue Syndrome, ChronicFemaleFeverHumansHydroxychloroquineLopinavirMaleAntiviral AgentsDrug CombinationsHydroxychloroquineLopinavirlopinavir-ritonavir drug combinationOseltamivirRitonavirChronic fatigue syndrome / myalgic encephalomyelitisCOVID-19Post-COVID morbiditiesPost-traumatic stress disorder

Identifiers

PMID33528827
PMCPMC7852482
OpenAlexW3128565996

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.